臺北榮民總醫院口腔醫學部

:::

陳志丞 (Chih-Cheng Chen)

複診掛號初診掛號

[簡介]

學歷
經歷
現職：
- 2024- 迄今台北榮總腫瘤醫學部主治醫師
- 2024- 迄今國立陽明交通大學醫學系教授
- 2017- 迄今中華民國血液病學會理事
經歷：
- 2014- 2024 嘉義長庚醫院血液腫瘤科醫師研究員
- 2018- 2024 長庚大學醫學系教授
- 2021- 2024 嘉義長庚醫院臨床試驗中心主任
- 2021- 2024 嘉義長庚骨髓增生性腫瘤中心主任
- 2016- 2017 嘉義長庚醫院醫學研究部主任
- 2011- 2017 嘉義長庚醫院血友病中心主任
- 2012- 2015 嘉義長庚醫院內科部副部長
- 2009- 2012 嘉義長庚醫院血液腫瘤科主任
- 2005- 2024 嘉義長庚醫院血液腫瘤科主治醫師
- 2004- 2005 國家衛生研究院癌症研究所研究醫師
- 2000- 2004 台北榮總血液科總醫師
- 1997- 2000 台北榮總內科部住院醫師/總醫師
醫療專長
1. 血液惡性疾病（骨髓增生性腫瘤、淋巴癌、血癌、多發性骨髓瘤）、貧血、其他血球減少症、造血幹細胞移植
證照

中華民國內科專科醫師、中華民國血液病專科醫師、中華民國腫瘤內科專科醫師、中華民國血液及骨髓移植專科醫師
語言專長

國語、英語、台語

[著作]

Chen CC, Kuo MC, Wang YH, Pei SN, Huang ML, Chen CC, Huang CE, Chen YY, Shih LY. Treatment outcome and germline predictive factors of ropeginterferon alpha-2b in myeloproliferative neoplasm patients. Cancer Medicine. 2024;13:e7166.
Chen CC, Chen JL, Lin AJ, Yu LH, Hou HA. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis. Ann Hematol. 2024;103:1947-65.
Wang YH, Chen YJ, Lai YH, Wang MC, Chen YY, Wu YY, Yang YR, Tsou HY, Li CP, Hsu CC, Huang CE, Chen CC*. Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 CALR-Mutated MPN. Int J Mol Sci. 2023;24:8747.
Hsu CC, Wang YH, Chen YY, Chen YJ, Lu CH, Wu YY, Yang YR, Tsou HY, Li CP, Huang CE, Chen CC*. The Genomic Landscape in Philadelphia-Negative Myeloproliferative Neoplasm Patients with Second Cancers. Cancers 2022;14:3433.
Huang CE, Chang JJ, Wu YY, Huang SH, Chen WM, Hsu CC, Lu CH, Hung CH, Shi CS, Lee KD, Chen CC*, Chen MC. Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection. Biomed J 2022;45;788-797.
Chen CC, Hsu CC, Chen SL, Lin PH, Chen JP, Pan YR, Huang CE, Chen YJ, Chen YY, Wu YY, Yang MH*. RAS mediates BET inhibitor-endued repression of lymphoma migration and prognosticates a novel proteomics-based subgroup of DLBCL through its negative regulator IQGAP3. Cancers 2021;13:5024.
Hsu CC, Chen YJ, Huang CE, Wu YY, Wang MC, Pei SN, Liao CK, Lu CH, Chen PT, Tsou HY, Li CP, Chuang WH, Chuang CK, Yang CY, Lai YH, Lin YH, Chen CC*. Molecular Heterogeneity Unraveled by Single-Cell Transcriptomics in Patients with Essential Thrombocythemia. Br J Haematol 2020;188:707-722.
Hsu CC, Huang CE, Wu YY, Chen YY, Lung J, Leu YW, Li CP, Tsou HY, Chuang WH, Lu CH, Chen CC*. Quantitative Competitive Allele-Specific TaqMan Duplex PCR (QCAST-Duplex PCR) Assay: A Refined Method For Highly Sensitive And Specific Detection Of JAK2V617F Mutant Allele Burdens. Haematologica 2018;103:e454.
Chen CC, You JY, Lung J, Huang CE, Chen YY, Leu YW, Ho HY, Li CP, Lu CH, Lee KD, Hsu CC, and Gau JP. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasms. Haematologica 2017;102:509-18.
Chen CC, You JY, Gau JP, Huang CE, Chen YY, Tsai YH, Chou HJ, Lung J, Yang MH. Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia. Blood Cancer Journal 2015;5:e339.
Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol 2014;93:2029-36.
Chen CC, Chu CB, Liu KJ, Huang CY, Chang JY, Pan WY, Chen HH, Chen YH, Lee KD, Chen MF, Kuo CC, Chen LT. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: The role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochem Pharmacol. 2013;86:872-87.
Chen CC, Chen LT, Tsou TC, Pan WY, Kuo CC, Liu JF, Yeh SC, Tsai FY, Hsieh HP, Chang JY. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer 2007;97:334-44.
Chen CC, Yang CF, Yang MH, Lee KD, Kwang WK, Yu YB, You JY, Tzeng TH, Ho CH, Chau WK, Hsu HC, Gau JP. Pre-treatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Ann Oncol 2005;16:1366-73.